Progress in Antiretroviral Drug Delivery Using Nanotechnology

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2010 Oct 20

PMID 20957115

Citations 42

Authors

Rama Mallipeddi

Lisa Cencia Rohan

Affiliations

Soon will be listed here.

Abstract

There are currently a number of antiretroviral drugs that have been approved by the Food and Drug Administration for use in the treatment of human immunodeficiency virus (HIV). More recently, antiretrovirals are being evaluated in the clinic for prevention of HIV infection. Due to the challenging nature of treatment and prevention of this disease, the use of nanocarriers to achieve more efficient delivery of antiretroviral drugs has been studied. Various forms of nanocarriers, such as nanoparticles (polymeric, inorganic, and solid lipid), liposomes, polymeric micelles, dendrimers, cyclodextrins, and cell-based nanoformulations have been studied for delivery of drugs intended for HIV prevention or therapy. The aim of this review is to provide a summary of the application of nanocarrier systems to the delivery of anti-HIV drugs, specifically antiretrovirals. For anti-HIV drugs to be effective, adequate distribution to specific sites in the body must be achieved, and effective drug concentrations must be maintained at those sites for the required period of time. Nanocarriers provide a means to overcome cellular and anatomical barriers to drug delivery. Their application in the area of HIV prevention and therapy may lead to the development of more effective drug products for combating this pandemic disease.

Citing Articles

Solid Lipid Nanoparticles as an Innovative Lipidic Drug Delivery System.

Waghmare S, Palekar R, Potey L, Khedekar P, Sabale P, Sabale V Pharm Nanotechnol. 2024; 13(1):22-40.

PMID: 38317470 DOI: 10.2174/0122117385271393231117063750.

Enhanced Antidepressant Activity of Nanostructured Lipid Carriers Containing Levosulpiride in Behavioral Despair Tests in Mice.

Arif S, Khan M, Zaman S, Sarwar H, Raza A, Sarfraz M Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765028 PMC: 10535960. DOI: 10.3390/ph16091220.

New insights from nanotechnology in SARS-CoV-2 detection, treatment strategy, and prevention.

Solanki R, Shankar A, Modi U, Patel S Mater Today Chem. 2023; 29:101478.

PMID: 36950312 PMC: 9981536. DOI: 10.1016/j.mtchem.2023.101478.

Novel Nanotechnology-Based Approaches for Targeting HIV Reservoirs.

Fotooh Abadi L, Damiri F, Zehravi M, Joshi R, Pai R, Berrada M Polymers (Basel). 2022; 14(15).

PMID: 35956604 PMC: 9370744. DOI: 10.3390/polym14153090.

Bionized Nanoferrite Particles Alter the Course of Experimental Cryptococcus neoformans Pneumonia.

Liporagi Lopes L, Korangath P, Dos Santos Jr S, Gabrielson K, Ivkov R, Casadevall A Antimicrob Agents Chemother. 2022; 66(4):e0239921.

PMID: 35293784 PMC: 9017294. DOI: 10.1128/aac.02399-21.

References

Gagne J, Desormeaux A, Perron S, Tremblay M, Bergeron M . Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim Biophys Acta. 2002; 1558(2):198-210. DOI: 10.1016/s0005-2736(01)00432-1. View

Mallipeddi R, Rohan L . Nanoparticle-based vaginal drug delivery systems for HIV prevention. Expert Opin Drug Deliv. 2009; 7(1):37-48. DOI: 10.1517/17425240903338055. View

Lai S, Wang Y, Wirtz D, Hanes J . Micro- and macrorheology of mucus. Adv Drug Deliv Rev. 2009; 61(2):86-100. PMC: 2736374. DOI: 10.1016/j.addr.2008.09.012. View

Kuo Y . Loading efficiency of stavudine on polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate copolymer nanoparticles. Int J Pharm. 2005; 290(1-2):161-72. DOI: 10.1016/j.ijpharm.2004.11.025. View

Cone R . Barrier properties of mucus. Adv Drug Deliv Rev. 2009; 61(2):75-85. DOI: 10.1016/j.addr.2008.09.008. View

Kawata K, Osawa M, Okabe S . In vitro toxicity of silver nanoparticles at noncytotoxic doses to HepG2 human hepatoma cells. Environ Sci Technol. 2009; 43(15):6046-51. DOI: 10.1021/es900754q. View

Sarker D . Engineering of nanoemulsions for drug delivery. Curr Drug Deliv. 2005; 2(4):297-310. DOI: 10.2174/156720105774370267. View

Jain K . Nanodiagnostics: application of nanotechnology in molecular diagnostics. Expert Rev Mol Diagn. 2003; 3(2):153-61. DOI: 10.1586/14737159.3.2.153. View

Kuo Y, Su F . Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm. 2007; 340(1-2):143-52. DOI: 10.1016/j.ijpharm.2007.03.012. View

10.

Yang H, Parniak M, Isaacs C, Hillier S, Rohan L . Characterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781. AAPS J. 2008; 10(4):606-13. PMC: 2628202. DOI: 10.1208/s12248-008-9070-3. View

11.

Buchanan C, Buchanan N, Edgar K, Little J, Ramsey M, Ruble K . Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-beta-cyclodextrin formulations. Biomacromolecules. 2007; 9(1):305-13. DOI: 10.1021/bm700827h. View

12.

Dutta T, Garg M, Jain N . Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur J Pharm Sci. 2008; 34(2-3):181-9. DOI: 10.1016/j.ejps.2008.04.002. View

13.

Zara G, Cavalli R, Fundaro A, Bargoni A, Caputo O, Gasco M . Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol Res. 1999; 40(3):281-6. DOI: 10.1006/phrs.1999.0509. View

14.

Vyas T, Shahiwala A, Amiji M . Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int J Pharm. 2007; 347(1-2):93-101. PMC: 2213794. DOI: 10.1016/j.ijpharm.2007.06.016. View

15.

das Neves J, Amiji M, Bahia M, Sarmento B . Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv Drug Deliv Rev. 2009; 62(4-5):458-77. DOI: 10.1016/j.addr.2009.11.017. View

16.

Flasher D, Konopka K, Chamow S, Dazin P, Ashkenazi A, Pretzer E . Liposome targeting to human immunodeficiency virus type 1-infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG). Biochim Biophys Acta. 1994; 1194(1):185-96. DOI: 10.1016/0005-2736(94)90219-4. View

17.

Gupta U, Jain N . Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv Drug Deliv Rev. 2009; 62(4-5):478-90. DOI: 10.1016/j.addr.2009.11.018. View

18.

Oka H, Onaga T, Koyama T, Guo C, Suzuki Y, Esumi Y . Syntheses and biological evaluations of carbosilane dendrimers uniformly functionalized with sialyl alpha(2-->3) lactose moieties as inhibitors for human influenza viruses. Bioorg Med Chem. 2009; 17(15):5465-75. DOI: 10.1016/j.bmc.2009.06.035. View

19.

Jin S, Bi D, Wang J, Wang Y, Hu H, Deng Y . Pharmacokinetics and tissue distribution of zidovudine in rats following intravenous administration of zidovudine myristate loaded liposomes. Pharmazie. 2005; 60(11):840-3. View

20.

Harouse J, Bhat S, Spitalnik S, Laughlin M, Stefano K, Silberberg D . Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. Science. 1991; 253(5017):320-3. DOI: 10.1126/science.1857969. View